Here are the 10 most expensive Medicare Part B drugs by brand name, generic name and total price.
1. Eylea/Aflibercept: $2.21 billion
2. Rituxan/Rituximab: $1.67 billion
3. Neulasta/Pegfilgrastim: $1.38 billion
4. Remicade/Infliximab: $1.34 billion
5. Avastin/Bevacizumab: $1.11 billion
6. Prolia/Denosumab: $1.09 billion
7. Lucentis/Ranibizumab: $1.04 billion
8. Herceptin/Trastuzumab: $703.57 million
9. Orencia/Abatacept: $586.53 million
10. Alimta/Pemetrexed Disodium: $511.82 million.
Here are the 10 most expensive Medicare Part D drugs by brand name, generic name and total price.
1. Harvoni/Ledipasvir & Sofosbuvir: $4.40 billion
2. Revlimid/Lenalidomide: $2.66 billion
3. Lantus Solostar/Insulin Glargine: $2.53 billion
4. Januvia/Sitagliptin Phosphate: $2.44 billion
5. Crestor/Rosuvastatin Calcium: $2.32 billion
6. Advair Diskus/Fluticasone/Salmeterol: $2.32 billion
7. Lyrica/Pregabalin: $2.10 billion
8. Xarelto/Rivaroxaban: $1.96 billion
9. Eliquis/Apixaban: $1.93 billion
10. Spiriva/Tiotropium Bromide: $1.82 billion
More articles on coding, billing and collections:
4 ASCs & outpatient facilities achieving certification and accreditation — April 2018
‘This is simply wrong’ — HHS Sec. Alex Azar criticizes high prices in hospitals compared to physician offices
NueHealth, Rothman Institute, Jefferson Health joint venture plans to reopen ASC, double case volume to 4k — 6 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
